BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KR…

BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C ...

BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook

On 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and ...
Business Wire

BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRAS G12C NSCLC

- The first patient has been dosed in the ONKORAS-101 trial for the study of BBO-8520 in adult subjects with KRAS G12C non-small cell lung cancer - BBO-8520 is a first-in-class orally bioavailable and ...
Nasdaq

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
Medical Xpress

Cancer drug candidate developed using supercomputing and AI blocks tumor growth without toxic side effects

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect. The compound was developed by Lawrence Livermore National ...